FDA approves Cue Health’s at-home COVID-19 test (NASDAQ:HLTH)

0


Coronavirus

loops7

The U.S. Food and Drug Administration (FDA) on Tuesday said it had approved Cue Health’s (NASDAQ:HLTH) at-home COVID-19 test, the first ever to be granted authorization through a traditional premarket review process.

HLTH stock was down 4% to $0.57 after hours.

HLTH’s



Source link

Leave A Reply

Your email address will not be published.